HanchorBio Inc.
1.12.2023 13:03:40 CET | ACCESS Newswire | Press release
SAN FRANCISCO, CA and TAIPEI, TAIWAN / ACCESSWIRE / December 1, 2023 / HanchorBio Inc., a global clinical-stage biotechnology company focusing on the discovery and development of innovative immuno-biomedicines to treat a wide variety of patients suffering from hard-to-treat solid tumors or hematological malignancies, today announced the acceptance of poster presentation at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) 2023 Annual Congress, taking place in Geneva, Switzerland and online from December 6-8, 2023.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.Details of the presentation are as follows. The full abstracts will be made available on the ESMO website on Thursday, 30 November 2023 at 00:05 CET.
Title: An Engineered Ligand-Trap Biologic Targeting the CD47 Signaling Pathway for Cancer Treatment with Superb Efficacy and Safety Profiles
Presenter: Sean Juo, Ph.D., President and Chief Scientific Officer of HanchorBio
Location: Palexpo, Geneva, Switzerland
Presentation Number: #10951
Date and Time: Thursday, 7 December 2023 at 12:00-13:00 CET
Highlights from the Preclinical Data-
Key findings from the preclinical studies of HCB101 targeting the SIRPa- CD47 pathway include:
- HCB101 triggered strong phagocytic reactions against tumor cells but not red blood cells;
- HCB101 consistently showed excellent efficacy against hematological and solid malignancies in 14 human tumor xenograft models;
- Quantitative RNA transcriptional analysis indicated that HCB101 triggered drastic changes in gene expression inside the tumor compared to other competing molecules, suggesting a unique MOA underlying HCB101's superior efficacy;
- No adverse reaction was observed in cynomolgus monkey toxicology studies, indicating a good safety profile;
- HCB101 is currently being evaluated in a multi-regional, multi-center clinical study (NCT05892718) in the United States and Taiwan.
About HCB101
Discovered through structure-guided protein design which was further supplemented with relevant screening technologies, HCB101 is an engineered extracellular IgV domain of SIRPα fused to the Fc region of IgG4. HCB101 triggers potent phagocytic activity of macrophages by blocking the "do not eat" signal between macrophages and the tumor cells. Based on the extensive in-vitro and in-vivo preclinical data, HCB101 is potentially a much safer and more potent biologic than the anti-CD47 monoclonal antibodies and other SIRPα fusion proteins currently being investigated in clinical trials. Furthermore, quantitative RNA transcriptional analysis indicated that HCB101 triggered distinct gene expression profiles inside the tumor and in the tumor microenvironment compared to other relevant clinical candidates, suggesting that HCB101 might exhibit unique mechanisms of action. With IND clearance from the U.S. FDA and Taiwan FDA, HCB101 is currently being investigated in a multi-regional, multi-center, open-label, dose-finding clinical trial (NCT05892718) of adults with advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma in the United States and Taiwan. Using HCB101 as the foundation, our multi-functional Fc-based designer biologics (FBDB™) platform pipeline includes other immune-modulating molecules targeting both adaptive and innate immunity to provide novel and efficacious treatments to patients suffering from difficult-to-treat cancers and other debilitating diseases.
About HanchorBio
Based in Taipei, Shanghai, and the San Francisco Bay Area, HanchorBio is a global clinical-stage biotechnology company focusing on immuno-oncology. The Company is led by an experienced team of pharmaceutical industry veterans with a proven track record of success in biologics discovery and global development to transcend current cancer therapies. Committed to reactivating the immune system to fight against diseases, the proprietary Fc-based designer biologics (FBDB™) platform enables unique biologics with diverse multi-targeting modalities to unleash both innate and adaptive immunity to overcome the current inadequacies of anti-PD1/L1 therapies. The FBDB™ platform has successfully delivered proof-of-concept data in several in vivo tumor animal models. By making breakthroughs in multi-functional innovative molecular configurations in R&D and improving the manufacturing process in CMC, HanchorBio develops transformative medicines to address unmet medical needs.
For more information, please visit HanchorBio or follow us on LinkedIn
Contact Information
Scott Liu
Founder, Chairman and CEO
scott_liu@hanchorbio.com
Yuehua Cong
Chief Business Officer
yuehua_cong@hanchorbio.com
SOURCE: HanchorBio Inc.
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/811807/hanchorbio-to-present-at-the-esmo-immuno-oncology-2023-annual-congress
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Datavault AI Further Expands IP Portfolio with New Patent Issuance and Notices of Allowance22.4.2026 16:00:00 CEST | Press release
Builds on December 2025 Content Licensing Patents and Carbon Credit Tokenization Grant; Strengthens IP Moat Across Data Valuation, Virtual Funding, and Tokenized Tax Prep PHILADELPHIA, PA / ACCESS Newswire / April 22, 2026 / Datavault AI Inc. ("Datavault AI" or the "Company") (NASDAQ:DVLT), a leader in AI-driven data monetization, credentialing, digital engagement, and real-world asset ("RWA") tokenization technologies, today announced the issuance of U.S. Patent No. 12,596,819 and Notices of Allowance on two additional U.S. patent applications. This milestone builds directly on the Company's December 2025 issuance of two foundational patents for blockchain-driven content licensing and tokenized monetization - further expanding its robust intellectual property portfolio headlined by the industry-defining Carbon Credit Tokenization Patent. Key Highlights for Investors One newly issued patent and two Notices of Allowance extend protection across three high-value platforms: AI-validated d
Karbon-X Highlights SkyXero on Earth Day, Bringing Real-Time Climate Action to Travel22.4.2026 15:15:00 CEST | Press release
Company underscores leadership use and introduces matched contribution initiative to support verified climate projects. CALGARY, AB / ACCESS Newswire / April 22, 2026 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions provider operating across compliance and voluntary carbon markets, today marked Earth Day by highlighting SkyXero, its mobile application designed to help individuals understand and act on the emissions associated with their air travel. As global travel continues to increase, flight emissions remain one of the least visible and least understood components of individual environmental impact. SkyXero addresses this gap by enabling users to calculate emissions associated with any commercial flight and support verified climate projects such as reforestation, renewable energy, and carbon reduction initiatives. To reinforce its commitment to practical climate accountability, Karbon-X has applied SkyXero internally across its l
DOJO AI Raises $6M to Power Agentic Marketing Platform, Transforming Data Into Business Impact22.4.2026 14:00:00 CEST | Press release
Backed by Armilar and Heartfelt VC, the company serves over 100 customers across the U.S. and U.K., including CoinDesk, Morningstar, Broadvoice, PensionBee, CovertSwarm and Refine Labs LONDON, UK AND LISBON, PORTUGAL / ACCESS Newswire / April 22, 2026 / DOJO AI, the intelligent marketing system that brings a new class of integrated AI to marketing teams, today announced a $6 million seed round at a $30 million valuation. The round was led by Armilar, with participation from Heartfelt VC. The funding will support continued product development and accelerated expansion in the United States. DOJO AI introduces a new paradigm for marketing technology, powering what the industry is beginning to call agentic marketing: a system where AI agents don't just report on performance but take action on it. The platform watches paid and organic campaigns around the clock, audits SEO and Answer Engine Optimization visibility continuously, generates brand-aligned content, and feeds every outcome back i
GoodData Launches Agent Builder for Enterprise AI22.4.2026 12:00:00 CEST | Press release
Enterprises can now deploy governed analytics agents in minutes, with full control over configuration, context, and scale. SAN FRANCISCO, CA / ACCESS Newswire / April 22, 2026 / GoodData, the AI-powered analytics and decision intelligence platform, today announced the launch of Agent Builder, a new capability that expands its platform with a dedicated environment for building, configuring, and scaling AI agents across the enterprise. Agent Builder enables organizations to move beyond single-purpose AI assistants and instead deploy multiple, purpose-built analytics agents that can be precisely configured, governed, and scaled across customers, workspaces, and user groups. The launch addresses a growing enterprise challenge: while organizations are rapidly moving from experimentation to production with AI agents, consistent, secure, and scalable deployment across business units remains difficult without significant custom engineering. From Experimentation to Enterprise Scale While most a
Karbon-X Reports $60.8 Million in Nine-Month Revenue and Files Q3 Form 10-Q21.4.2026 17:40:00 CEST | Press release
CALGARY, AB / ACCESS Newswire / April 21, 2026 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or the "Company"), a vertically integrated climate solutions company, today announced that it has filed its Quarterly Report on Form 10-Q for the nine months ended February 28, 2026. The filing reflects Karbon-X's continued expansion in global carbon markets, with year-to-date revenue of $60.8 million, a strengthened balance sheet, and a growing project pipeline, supported by increasing demand for high-integrity carbon solutions. "Karbon-X has scaled significantly over the past twelve months, with nine-month revenue of $60.8 million reflecting strong commercial execution across our trading operations," said Chad Clovis, Chief Executive Officer of Karbon-X Corp. "While Q3 trading volumes reflected expected variability in settlement timing across international markets, our underlying business continues to strengthen. We remain focused on disciplined growth across trading, project development, and dig
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom